Rhenman & Partners Asset Management Ab Amarin Corp Plcuk Transaction History

Rhenman & Partners Asset Management Ab

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2020 Jan 19, 2021	SELL	$4.04 - $5.31 $1.21 Million - $1.59 Million	-300,000 Closed	0 $0
Q3 2020 Oct 13, 2020	SELL	$3.64 - $7.76 $819,000 - $1.75 Million	-225,000 Reduced 42.86%	300,000 $1.26 Million
Q2 2020 Jul 16, 2020	SELL	$4.78 - $8.26 $119,500 - $206,500	-25,000 Reduced 4.55%	525,000 $3.63 Million
Q1 2020 Apr 16, 2020	BUY	$4.0 - $21.53 $600,000 - $3.23 Million	150,000 Added 37.5%	550,000 $2.2 Million
Q3 2019 Oct 16, 2019	BUY	$13.89 - $23.16 $683,388 - $1.14 Million	49,200 Added 14.03%	400,000 $6.06 Million
Q2 2019 Jul 22, 2019	SELL	$16.27 - $20.51 $325,400 - $410,200	-20,000 Reduced 5.39%	350,800 $6.8 Million
Q1 2019 Apr 11, 2019	BUY	$12.61 - $22.33 $3.41 Million - $6.05 Million	270,800 Added 270.8%	370,800 $7.7 Million
Q4 2018 Feb 05, 2019	BUY	$12.41 - $22.98 $1.24 Million - $2.3 Million	100,000 New	100,000 $1.36 Million

177

65.1M

258K

98K

Ticker AMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 403,206,016
Market Cap $190M
Description
Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for r...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.